Kawasaki Disease from a Single-Referral Center in Morocco with Emphasis on Diagnosis Delay and Treatment Onset
- PMID: 40637622
- PMCID: PMC12257779
- DOI: 10.5152/TurkArchPediatr.2025.25053
Kawasaki Disease from a Single-Referral Center in Morocco with Emphasis on Diagnosis Delay and Treatment Onset
Abstract
Objective: Kawasaki disease (KD) is one of the most common systemic vasculitides and a cause of acquired heart disease in children. The aim was to provide an epidemiological picture of KD with an emphasis on cardiac involvement in Morocco. Materials and Methods: This is a cross-sectional observational study recruiting patients with KD between January 2019 and December 2023. Diagnosis was based on 2017 American Heart Association criteria under the supervision of an expert. Statistical analysis was carried out using the chi-square, Mann-Whitney U, and Fisher's exact tests. Results: Sixty-nine patients were admitted; the mean age was 36 months, the sex ratio was 1.6 (male:female), and the mean days to the first consultation was 10.1. Thirty-nine cases met the criteria for complete forms and 30 for incomplete forms. Coronary dilatations and aneurysms were found in 20 and 7 patients respectively, including 3 giant aneurysms. All patients were treated with intravenous immunoglobulin (IVIG) except 1 and acetylsalicylic acid (ASA), and 23.1% received corticosteroids. Fourteen patients (20.3%) were resistant and 4.3% could benefit from a rescue treatment including second IVIG, Anakinra, and corticosteroids. Six predictive factors of coronary involvement were analyzed and were significant for age ≤ 12 months and ≥ 60 months and delay in IVIG infusion of more than 10 days (P= .045/P = .017). Conclusion: This study demonstrates the importance of raising awareness of KD among primary care physicians, given that a significant proportion of patients were referred from day 10 of fever onward, and paying more attention to extreme ages where coronary involvement is more common.
Conflict of interest statement
Figures
Similar articles
-
Intravenous immunoglobulin for the treatment of Kawasaki disease.Cochrane Database Syst Rev. 2023 Jan 25;1(1):CD014884. doi: 10.1002/14651858.CD014884.pub2. Cochrane Database Syst Rev. 2023. PMID: 36695415 Free PMC article.
-
Sexual Harassment and Prevention Training.2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 36508513 Free Books & Documents.
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.Cochrane Database Syst Rev. 2022 Mar 11;3(3):CD013130. doi: 10.1002/14651858.CD013130.pub2. Cochrane Database Syst Rev. 2022. PMID: 35274741 Free PMC article.
-
Sertindole for schizophrenia.Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
References
-
- McCrindle BW, Rowley AH, Newburger JW. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927 e999. (doi: 10.1161/CIR.0000000000000484) . Erratum in: Circulation. 2019;140(5): e181 e184. (doi: ) - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous